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Abstract
In 1963 George Mathé announced to the world that he had cured a patient of leukaemia by means of a bone-marrow
transplant. Since than much progress has been made and nowadays Hematopoietic Stem Cell Transplantation (HSCT)
is considered the most effective treatment of numerous severe haematological diseases. Gynaecological complications
in HSCT women represent a serious concern for these patients, but often underestimated by clinicians in the view of
Overall Survival. The main gynaecological complications of HSCT are represented by: premature ovarian failure (POF),
thrombocytopenia-associated menorrhagia, genital symptoms or sexual problems in course of chronic GVHD (cGVHD),
osteoporosis, secondary solid tumours due to immunosuppressive drugs to treat cGVHD and severity of cGVHD, and
fertility and pregnancy issues. In particular fertility-related issues are always more relevant for patients, whose life
expectation is constantly growing up after HSCT.
Thus, taking care of a patient undergoing HSCT should primarily include gynaecological evaluation, even before
conditioning regimen or chemotherapy for the underlying malignancy, as, in our opinion, it is of great importance to
ensure a complete diagnostic work-up and intervention options to guarantee maximum reproductive health and a
better quality of life in HSCT women.
The present review aims at describing principal features of the aforementioned gynaecological complications of HSCT,
and to define, on the basis of current international literature, a specific protocol for the prevention, diagnosis,
management and follow-up of gynaecological complications of both autologous and heterologous transplantation,
before and after the procedure.
Background
In 1963 George Mathé announced to the world that he had
cured a patient of leukaemia by means of a bone-marrow
transplant [1].
Since than much progress has been made and nowadays
Hematopoietic Stem Cell Transplantation (HSCT) is
considered the most effective treatment of numerous
severe haematological diseases [2]. The most common
sources of multipotent hematopoietic stem cells are
bone marrow, peripheral blood or umbilical cord
blood. Autologous transplantation – autograft or auto-
HSCT– (hematopoietic cell transplantation in the same
patient after appropriate treatment) differs from allogeneic
transplantation (allograft or allo-HSCT), in which the
marrow comes from a donor [2, 3].
Allo-HSCT is associated with a more severe derangement
of the immune system than auto-HSCT. Main factors
with important effects on post-transplantation period
are: conditioning regimens administered to avoid graft
rejection, cytokine storm triggered by transplantation,
multiple immunosuppressive therapy to prevent graft-
versus-host disease, and frequent development of
acute/chronic multi-organ Graft Versus Host Disease
(GVHD) [4].
Gynaecological issues before and after HSCT have
been under investigation since the early 90s [5, 6].
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Actually the main gynaecological complications of HSCT
are represented by: premature ovarian failure (POF),
thrombocytopenia-associated menorrhagia, genital symp-
toms or sexual problems in course of chronic Graft Versus
Host Disease (cGVHD), osteoporosis, secondary solid
tumours due to immunosuppressive drugs to treat
cGVHD and severity of cGVHD [7, 8], and fertility and
pregnancy issues. Nonetheless, these last issues remain
poorly investigated in the international literature with only
some reports of successful pregnancies [9].
Therefore, fertility preservation in women undergoing
HSCT should represent a major concern for the clin-
ician taking care of these patients, who have a risk
higher than 80 % of permanent amenorrhea after HSCT
with cyclophosphamide/total body irradiation (TBI) or
cyclophosphamide/busulfan [5, 10–12].
The first part of the present review aims at describing
principal features of the aforementioned main gynaeco-
logical complications of HSCT.
Otherwise, in the second part, which represents the
aim of the present paper, we define, on the basis of
current international literature, a specific protocol for
the prevention, diagnosis, management and follow-up of
gynaecological complications of both autologous and
heterologous transplantation, before and after the
procedure.
Methods
This review includes papers published in the English lan-
guage on Hematopoietic Stem Cell Transplantation and
Gynaecological complications since 1997 and identified
through a MEDLINE and EMBASE search using combi-
nations of the following subject heading terms:
Hematopoietic Stem Cell Transplantation, gynaecological
complications, cGVHD, fertility, fertility preservation,
reproduction. Of the retrieved articles, 73 papers regard-
ing gynaecological complications of HSCT were added,
together with guidelines of different societies and inter-
national recommendations from experts were added.
Finally, our specific protocol for the prevention, diagnosis
and treatment of gynaecological complications before and
after HSCT women is described.
Gynaecological complications of HSCT
POF
POF, also known as ovarian insufficiency, is characterized
by loss of normal ovarian function before the age of 40
and usually occurs as secondary amenorrhea associated
with hypergonadotropic hypogonadism, and reduced
volumes of ovaries and uterus [4].
POF is characterized by symptoms of oestrogen defi-
ciency, such as hot flushes, night sweats, mood disorders,
sleep disorders, lack of concentration, arthralgia, impaired
sexual function and loss of reproductive potential, that
have a negative impact on quality of life [4, 7].
Lack of oestrogens at an early age prevents the develop-
ment of secondary sex characteristics, increases the risk
for osteoporosis, cognitive impairment and cardiovascular
disease, frequently observed in women after HSCT [7, 13].
POF is the most frequent complication after stem cell
transplantation for haematological malignancies, occur-
ring in more than 90 % of women [14, 15]. Indeed,
conditioning regimens consisting of high-dose antiblastic
treatments associated or not with TBI, precede both
auto- and allo-HSCT procedures, causing gonadal dam-
age [4]. Moreover, allo-HSCT can be followed by acute
or chronic GVHD and long-lasting steroid treatment,
which can further increase ovarian damage [4]. Risk
factors for gonadal damage in women undergoing HSCT
are summarized in Table 1.
Thrombocytopenia-associated menorrhagia
Menorrhagia is defined as heavy regular menstrual cycles
with more than 80 ml of blood loss/cycle or cycle
duration longer than 7 days.
After different conditioning regimens, women in repro-
ductive age may experience thrombocytopenia-associated
menorrhagia, especially if they had experienced regular or
irregular vaginal bleeding before HSCT [16]. This condi-
tion is a serious complication in young female oncology
patients who suffer from severe thrombocytopenia during
myelosuppressive treatment, associated with significant
morbidity. Consequently, effective management is neces-
sary to prevent adverse outcomes [17].
Actually, in order to manage thrombocytopenia-
associated menorrhagia, physicians can use the Menorrha-
gia Impact Questionnaire (MIQ) [17], developed to iden-
tify measurement domains, define meaningful, symptom
relief, measure magnitude of response, assess a patient’s
Table 1 Risk factors for gonadal damage in women undergoing
HSCTa
Patient relating factor
Pubertal stage Postpuberal > prepuberal
Age of HSCT >30 years
Underlying disease ALL, lymphomas
Treatment relating factor
Type of radiotherapy TBI, pelvic, inverted Y, fractionated doses
Chemotherapy Alkylating agents > other chemotherapy
Type of transplant Allo-HSCT > auto-HSCT
HSCT complications Presence of GVHD
ALL acute lymphoblastic leukaemia, allo allogeneic transplantation, auto
autologous transplatation, GVHD graft-versus-host disease, HSCT hematopoietic
stem cell transplant, TBI “total body” irradiation
Symbol (>) means more than
a modified from Orio et al. [4]
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ability to perform physical functions, work, and participate
in social and leisure activities, as well as measures global
change in menstrual blood loss.
Gonadotropin-releasing hormone analogues (e.g., leupro-
lide) are promising therapies that have been shown to de-
crease vaginal bleeding during periods of thrombocytopenia
and to have minimal adverse effects other than those asso-
ciated with gonadal inhibition [16, 17]. In patients who ex-
perience menorrhagia despite preventive therapies, or in
patients who have thrombocytopenia and menorrhagia at
diagnosis, treatment is indicated. For these women, treat-
ment options may include platelet transfusions, antifibrino-
lytic therapy (e.g., tranexamic acid), continuous high-dose
oral contraceptives, cyclic progestins, or other therapies for
more refractory patients such as danazol, desmopressin,
and recombinant factor VIIa. Hormonal therapies are often
the mainstay of therapy in women with menorrhagia
secondary to thrombocytopenia, but data for these agents,
such as combined hormonal contraceptive pills, combined
hormonal contraceptive patch, depot medroxyprogesterone,
and oral norethindrone are sparse [16, 17]. The most robust
data for the treatment of menorrhagia are for tranexamic
acid [16, 17].
Genital symptoms of cGVHD
Chronic GVHD is a serious and common complica-
tion of allogeneic hematopoietic cell transplantation
(HCT), occurring in 30 % to 70 % of patients [18].
Chronic GVHD is a syndrome of variable clinical fea-
tures resembling autoimmune and other immunologic
disorders, with a pathophysiology involving inflamma-
tion, cell-mediated immunity, humoral immunity, and
fibrosis [19, 20].
Chronic GVHD of female genital tract was firstly de-
scribed in 1982: five cases of severe vaginal scarring suc-
cessfully treated with surgery (to remove scar tissue) and
use of oestrogen and vaginal dilators were described [21].
Pain, burning, dysuria, a feeling of redness and swelling,
perineal and perianal soreness, dryness and dyspareunia,
are nonspecific symptoms of female genital cGVHD.
Patients, who are sexually active, may recognize symptoms
earlier [19, 20].
Female genital cGVHD can cause complete vaginal
obstruction resulting in haematocolpos or hematometra,
which can manifest as cyclic pain and amenorrhea in
women taking HT or as difficulty in voiding in case of
vulvar adhesions [7]. Actually, female genital cGVHD is
well-recognized clinical condition, with a precise assess-
ment and scoring form recently developed [19].
Treatment options include: topical steroids, topical im-
munosuppressants (cyclosporine, tacrolimus), oestrogen
therapy applied locally to vulva and vagina, and surgery if
severe scarring is recognized [19].
Osteoporosis
Osteoporosis occurs when the creation of new bone
does not keep up with the removal of old bone [22].
Significant effects on bone metabolism resulting from
HSCT were observed [23, 24].
In particular, osteoporosis after HSCT is attributable to
the influence of multiple factors including myeloablative
conditioning regimens, huge cytokine re-lease at the time
of transplant, altered kidney, liver and bowel function
resulting in reduced intake and altered metabolism of
calcium and vitamin D, in allogeneic HSCT setting, long-
lasting high-dose steroids and cyclosporine-A [24]. There-
fore, in women of reproductive age this is also associated
with lack of oestrogens associated with secondary amenor-
rhea and gonadal failure due to the underlying illness with
its complications and treatments [23, 24].
Moreover, bone marrow transplantation recipients are
at risk of osteoporosis secondary to bone loss associated
with their illness and/or chemotherapy, particularly in
female autograft recipients, and in allograft recipients
secondary to GVHD and its treatment [25].
Few data are available so far on the treatment of bone
loss in HSCT recipients. Early diagnosis of osteoporosis
or early bone senescence in this particular population is
a major aim to promptly start appropriate supportive
measures, such as lifestyle modification, calcium and
vit-amin D supplementation or bisphosphonates [24].
Treatment of osteoporosis in women undergone HSCT
actually include hormonal therapy (HT), which has
been demonstrated to increase bone mineral density of
the hypogonadal patients [23].
Secondary solid tumours
One of the long-term complications associated with allo-
geneic hematopoietic stem cell transplantation is the de-
velopment of secondary malignancies [26–33]. Several
factors contribute to the development of secondary neo-
plasm: the radiation and chemotherapy used for condi-
tioning and for treatment of the primary malignancy,
and the profound immunosuppression that occurs post
transplant [26].
Indeed, the risk of new solid cancers after bone
marrow transplantation in different studies resulted to
be higher than in general population, in particular
after allo-HSCT [26–30]. In particular, two large co-
hort studies published by the IBMTR and EBMT have
confirmed the increased risk of secondary malignancy
post transplant [27, 28].
These studies found that older age of female recipients
or female donors, the number of immunosuppressive
agents used for treatment of cGVHD, TBI with overall
doses of 1000 cGy or higher, and the presence of
cGVHD were significant risk factors for the development
of secondary malignancy. The most frequent secondary
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solid tumours developed were: basal cancer cell skin
[31], squamous cell cancer skin [32], squamous cell can-
cer oral [33] and breast cancer [32].
Moreover, prolonged use of immunosuppressive drugs
to treat cGVHD and severity of cGVHD are risk factors
for the development of human papillomavirus (HPV)-re-
lated dysplasia and squamous cell carcinoma of the female
genital tract [34–36]. Thus, on one side, regular surveil-
lance by gynaecologic examination, including cervical
cytological testing, in these patients allows for early diag-
nosis and effective management of cervical abnormality
and decreases the burden of this potentially fatal, but
treatable, condition [35].
On the other side, the immunogenicity and efficacy of
quadrivalent HPV vaccine has not been tested in long-
term survivors after allo-HSCT [36].
Fertility and pregnancy issues
Fertility is clearly impaired after HSCT and the
reported overall conception rate is <1 % [7]. Currently
HSCT with cyclophosphamide/TBI or cyclophospha-
mide/busulfan leads to >80 % risk of permanent
amenorrhea in women [5, 7].
Nowadays, people with cancer are interested in dis-
cussing fertility preservation. Health care providers,
caring for adult and paediatric patients with cancer
(including medical oncologists, radiation oncologists,
gynaecologic oncologists, urologists, haematologists,
paediatric oncologists, surgeons, and others), should
address the possibility of infertility as early as possible
before treatment starts [11].
In particular, patients undergoing HSCT, usually,
have a restricted time-window to decide and under-
take fertility preservation strategies. In this view, the
classical oocytes/eggs freezing procedure could not
represent the best option to be proposed to patients
undergoing HSCT [5, 9]. Therefore, this procedure
presents 2 main problems, as it includes at least a
minimum of two-week-ovarian stimulation protocol.
The first problem is the use of gonadotropins, which
represent an open issue in cancer patients, and the
second question is the two-weeks’ delay in the start
of the conditioning regimen.
Actually, great effort is employing to improve both the
communication between patients and physicians about
fertility risks and preservation options, and the collabor-
ation among haematologists and fertility specialists to
give patients the opportunity to undergo well-timed and
complete reproductive counselling [5].
Novel perspectives include strategies such as ovar-
ian tissue freezing in young girls affected with various
haematological diseases [5, 37]. This state-of-the-art
procedure has been developed to preserve fertility in
cancer patients.
However, not all the patients are considered eligible
for cryopreservation strategies (i.e. due to need to start
chemotherapy immediately [5]), so current clinical re-
search is also focusing on agents which can prevent or
attenuate the ovotoxic effects of treatment would pro-
vide significant advantages over the existing fertility
preservation techniques, and would allow patients to
retain their natural fertility without the necessity for
costly, invasive and risky procedures [38].
Ovarian tissue cryopreservation
Ovarian tissue cryopreservation is an investigational
method of fertility preservation but has the advantage
of requiring neither a sperm donor nor ovarian stimula-
tion. Ovarian tissue is removed laparoscopically, a one
hour outpatient procedure that requires general anaes-
thesia, and frozen. At a later date, the ovarian tissue is
thawed and reimplanted. Primordial follicles can be
cryopreserved with great efficiency [10, 39, 40], but be-
cause of the initial ischemia encountered after ovarian
transplantation, a quarter or more of these follicles
might be lost, as shown in xenografting studies [41]. To
offset this relatively large loss, typically the cortex from
an entire ovary could be cryopreserved in adults. The
benefit of ovarian cryopreservation for women older
than 40 years of age is very uncertain because there are
too few primordial follicles remaining [42]. Ovarian tis-
sue cryopreservation has been performed in humans
for less than a decade, and the first ovarian transplant
procedure was reported in 2000 [43], and the first preg-
nancy after ovarian transplantation in 2004 [44]. Ovar-
ian tissue can be transplanted orthotopically to pelvis
[44, 45] or heterotopically to subcutaneous areas such
as the forearm or lower abdomen [46, 47]. Following
re-implantation of ovarian tissue, a successful recovery
of ovarian function is expected in almost all cases
within 3 to 6 months, with possible sustained longevity
of function of the transplanted tissue [48, 49].
To date, a total of 40 live births have been reported in
cancer patients after transplantation of frozen/thawed
ovarian tissue [50]. It is almost impossible to calculate a
precise pregnancy rate for transplantation of cryopre-
served ovarian tissue until a large cohort of patients has
had all their tissue transplanted [51].
Combining 80 cases from 4 fertility centres, the preg-
nancy rate (i.e. ratio between the number of women who
conceived and the number of transplanted women) with
the use of this technique was 25 % [52–55]. Overall, the
pregnancy rate with the use of cryopreservation of ovar-
ian tissue seems to be increasing [5, 51].
One concern with reimplanting ovarian tissue is the
potential for reintroduction of cancer cells. In patients
without evidence of systemic metastasis to other organs,
the likelihood of occult ovarian metastasis appears to be
Guida et al. Journal of Ovarian Research  (2016) 9:72 Page 4 of 8
low in the majority of cancers seen in young females, and
there are no reports of cancer recurrence after ovarian
transplantation [56, 57]. Thus, ovarian tissue screening to
detect malignant cells is currently performed to minimize
the risk of inadvertent transfer with the ovary [9].
Ovarian cryopreservation and transplantation procedures
should only be performed in centres with the necessary
expertise under IRB-approved protocols that include
follow-up for recurrent cancer, as this procedure has been
proven to be an effective, yet still experimental, technique
to preserve fertility in patients undergoing gonadotoxic
therapies [5, 10, 11].
GnRH analogues
Preserving patients’ natural fertility is the goal to which
each reproductive health caregiver would lead. Recent
data and reviews focus in particular on the use of GnRH
analogues, also known as LHRH analogues, in fertility
preservation of cancer patients undergoing cytotoxic
treatments [38, 58–63].
LHRH analogues are used in various clinical situations,
such as uterine fibroids, abnormal uterine bleeding, etc.
LHRH analogues are widely used in oncology, and their
mode of action is almost completely understood [58]. The
mechanism of action of these analogues is mainly based
on the inhibition of pituitary and gonadal function, but
they also exert a direct function on the ovaries and uterus.
Indeed, in germ cells, the cell cycle stage at the time of ex-
posure will define the molecular response to cytotherapy
[38, 57]. Between the primordial and antral follicle stages,
the oocyte is in the dictyate (prolonged diplotene) stage of
prophase I arrest [38]. Following the LH surge, the oocyte
is triggered to enter into the first meiotic M-phase, M1
[64]. Thus, cytotoxic drug-induced apoptotic pathways
have been well documented in growing follicles [65, 66].
On the other side, less is known on primordial follicles. A
novel theory of chemotherapy-induced destruction of
dormant follicles suggests that in vivo chemotherapy
triggers follicle activation and growth, causing burnout
and depletion of the ovarian reserve [67]. Histology
demonstrated both an absence of apoptosis in primordial
follicles together with an initiation of follicle growth
immediately following chemotherapy exposure, occurring
simultaneously with large follicle apoptosis [38].
Moreover, experimental data on mice show that intrao-
varian transplantation of primordial follicles fails to rescue
chemotherapy-injured ovaries [68].
In this view, recent literature suggests that GnRH ana-
logues could be protective of the ovarian reserve and
natural fertility in cancer patients [38, 69]. The majority
of clinical data comes from breast cancer patients, and
only two papers report data on women with lymphoma
[59, 70]. In particular, Triptorelin was not associated
with a significant decreased risk of POF in young
patients treated for lymphoma but may provide protection
of the ovarian reserve [59]. Indeed, AMH levels were sig-
nificantly higher in women who received cotreatment with
GnRH analogue (1.4 compared with 0.56 ng/ml) [59].
However, despite this research effort, ovarian suppression
with LHRH analogues during chemotherapy is still consid-
ered an experimental strategy to preserve fertility by some
international guidelines due to both the uncertainty regard-
ing the efficacy of this strategy and the absence of data on
pregnancies and long-term ovarian function [11, 69].
A clinic protocol for the management of gynaecological
complications before and after HSCT
On the basis of the current literature and of our previous
experience in the management of patients affected with dif-
ferent haematological diseases and/or treated with HSCT
we define a unified protocol for gynaecological manage-
ment in patients undergoing HSCT before and after the
procedure.
Diagnostic work-up before HSCT
Taking care of a patient undergoing HSCT should primarily
include gynaecological evaluation, even before conditioning
regimen or chemotherapy for the underlying malignancy.
Before HSCT a general gynaecological evaluation should
include: anthropometric characteristics, together with data
on haematological conditions, serum ferritin levels. Data
on menarche, including age and spontaneity of menarche
and menses, are essentials when evaluating these women.
Additionally, data on oestro-progestin (EP) replacement
therapy, previous pregnancies (spontaneous or obtained
with ovarian stimulation) and pelvic infections should be
included in the work-up. Then, a gynaecological pelvic
examination together with a sonographic scan, evaluating
uterine size, endometrial thickness and ovarian size should
be performed in each patient. In women of reproductive
age, ovarian reserve should be evaluated including Antral
Follicular Count (AFC) in the pelvic scan. Moreover, an
hormonal evaluation together, an HPG function analysis,
including basal levels of luteinizing hormone (LH),
follicular-stimulating hormone (FSH), estradiol (E2), pro-
lactin (PRL), anti-Mullerian hormone (AMH) and a thy-
roid profile (evaluation of blood levels of TSH, fT3, fT4,
anti-TPO, anti-TBG) should be offered to all fertile
women. This should be undertaken on day 2/3 of menses
in women with a regular menstrual cycle, or on any ran-
dom day in those with amenorrhea. Moreover, assessment
of the partner, when possible, should be undertaken [5].
Finally, thromboembolic risk evaluation and bone
density by MOC-DEXA of the vertebral district and of
the right and left femur should be collected and eventu-
ally amended [15]. Women undergoing allo-HSCT
should be assessed with the “Genital Tract Chronic
Graft-versus-Host Assessment and Scoring Form” [11].
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After that, an onco-fertility counselling should be
offered to all patients undergoing HSCT. This counsel-
ling analyses type and dose of the chemotherapy regi-
men proposed, method of administration (oral versus
intravenous), size and location of the radiation field and
its dose, need of adjuvant therapy [10, 71]. Specifically,
type of treatment and patients’ age are the most import-
ant factors to be taken into account when counselling
the patients [72]. Onco-fertility counselling should be
individualized, discussing both the absolute benefits of
the proposed anticancer treatment (e.g. adjuvant chemo-
therapy) and the risk of infertility for each individual,
proposing to each one the best treatment options.
Gynaecological diagnostic work-up in patients undergo-
ing HSCT is summarized in Table 2.
Gynaecological follow-up after HSCT
Gynaecological Follow-Up After HSCT should in-
clude a six-month complete evaluation including:
collection of symptoms, pelvic scan and hormonal
analysis of AMH, FSH, LH and estradiol. HPV-test
should be repeated every six-month. Bone mineral
density evaluation by MOC-DEXA of the vertebral
district and of the right and left femur should be re-
peated every twelve months. Women underwent
allo-HSCT should be assessed at each control with
the “Genital Tract Chronic Graft-versus-Host Assess-
ment and Scoring Form” [11].
Limitations
Gynaecological evaluation should start even before patients
become candidates for HSCT, but early when they become
diagnosed with a haematological malignancy. Indeed, even
if the conditioning regimens are at higher dosage respect to
conventional dosages, traditional chemotherapy however
results in gynaecological complications [38]. Furthermore,
current recommendations are not to allow patients to
undertake cryopreservation strategies between chemother-
apy treatments and to wait at least 6 months post chemo-
therapy before conception [32, 73].
Conclusion
Gynaecological complications in HSCT women repre-
sent a serious concern for these patients, but often
underestimated by clinicians in the view of Overall Sur-
vival. In particular fertility-related issues are always more
relevant for patients, whose life expectation is constantly
growing up after HSCT. Thus, in our opinion, it is of
great importance to ensure a complete diagnostic work-
up and intervention options to guarantee maximum re-
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